Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond.

Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-839/coif). RDC reports research funding to Columbia University from Amgen, Astellis, AstraZeneca, BioMed Valley, Bolt, Bristol-Myers Squibb, Corvus, Cstone, Foghorn, Ideaya, Immatics, Immunocore, InxMed, Iovance, Merck, Mirati, Novartis, Pfizer, Plexxikon, Regeneron, Roche/Genentech, received consulting fees from Alkermes, Bristol Myers Squibb, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento Therapeutics and Trisalus, payments or honoraria from PER, involved on Clinical/Scientific Advisory Boards for Celldex, Aura Biosciences, Chimeron and Rgenix, and received stock or stock options from Aura Biosciences, Chimeron, Rgenix. The other author has no conflicts of interest to declare.